2C-EF-FLY

2C-EF-FLY
Clinical data
Drug class	Serotonergic psychedelic; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name 2-[4-(2-fluoroethyl)-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl]ethanamine;
PubChem CID	162430129;
Chemical and physical data
Formula	C14H18FNO2
Molar mass	251.301 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COC2=C(C3=C(C(=C21)CCN)OCC3)CCF;
	InChI InChI=1S/C14H18FNO2/c15-5-1-9-11-3-7-18-14(11)10(2-6-16)12-4-8-17-13(9)12/h1-8,16H2; Key:NUNWOBYVOQRPKC-UHFFFAOYSA-N;

Pharmaceutical compound

2C-EF-FLY is a psychedelic drug of the phenethylamine, 2C, and FLY families.^[2]^[3] It is the FLY (benzodifuran) derivative of 2C-EF and is a fluorinated derivative of 2C-E-FLY.^[2]^[3]^[4] The in-vitro metabolism of 2C-EF-FLY and its monoamine oxidase (MAO) interactions have been described.^[2]^[3] 2C-EF-FLY produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It showed around half the potency of 2C-B-FLY and 2C-E-FLY in this assay, but was slightly more potent than 2C-I-FLY. 2C-EF-FLY was first described in the scientific literature by Lea Wagmann and colleagues in 2018 or 2019.^[5]^[2]^[3] It has been described as a novel designer drug.^[3]

References

1 2 3 4 Wagmann L, Brandt SD, Stratford A, Maurer HH, Meyer MR (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases" (PDF). Drug Testing and Analysis. 11 (2): 318–324. doi:10.1002/dta.2494. PMID 30188017.
1 2 3 4 5 Wagmann L, Hempel N, Richter LH, Brandt SD, Stratford A, Meyer MR (October 2019). "Phenethylamine-derived new psychoactive substances 2C-E-FLY, 2C-EF-FLY, and 2C-T-7-FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings". Drug Testing and Analysis. 11 (10): 1507–1521. doi:10.1002/dta.2675. PMID 31299701.
↑ Arbouche N, Gheddar L, Ameline A, Raul JS, Kintz P (2026). "Metabolic profiling of 2C-EF in human liver microsomes: Identification of major metabolites and biotransformation pathways". Toxicologie Analytique et Clinique. 38 (1): 57–64. doi:10.1016/j.toxac.2025.08.005. Retrieved 12 March 2026.
↑ Wagmann L (2018). Psychoactive substances as substrates or inhibitors of enzymes in drug metabolism and transport (Ph.D. thesis). Universität Des Saarlandes. doi:10.22028/D291-27544. Retrieved 12 March 2026.

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.